Bellevue Group AG Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001674546
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2026 · 148 positions · Total reported value $4.75B · Top-10 concentration 42.9% · Updated 2026-10-24
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
Turnover: 61.0% · 17 new · 64 cut · 24 exited
Active Share (vs S&P 500): 94.1% · vs QQQ: 96.5% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +12.4% · vs SPY -2.4% · Prev Value $4.20B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2026 13F filing, Bellevue Group AG disclosed 148 equity positions with a combined reported value of $4.75B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 42.9% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2026 were AMGN ($308.36M), VRTX ($287.42M), ARGX ($279.26M). By sector, the heaviest allocations are Health Care 92.6%, Industrials 1.7%. Versus the prior quarter, allocation shifted toward Health Care (+0.7pp) and away from Other (-0.7pp).
Versus the prior quarter, Bellevue Group AG opened 17 new positions, trimmed 64 and fully exited 24, a turnover rate of 61.0% of positions. The portfolio's overlap with the prior quarter was 76% of names.
The largest new positions opened in Q2 2026 were AVLN ($44.44M), CGON ($35.07M), SPTX ($23.89M).
Of the 24 positions fully exited versus the prior quarter, the largest were EWTX ($48.15M), INSP ($5.14M), PEN ($4.03M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2026)
- AVLN AVALYN PHARMA INC · $44.44M
- CGON CG ONCOLOGY INC · $35.07M
- SPTX SEAPORT THERAPEUTICS INC · $23.89M
- PVLA PALVELLA THERAPEUTICS INC NEW COM · $23.69M
- SYRE SPYRE THERAPEUTICS INC · $20.41M
- COAG HEMAB THERAPEUTICS HOLDINGS · $20.20M
- PBLS PARABILIS MEDICINES INC · $13.69M
- AURA AURA BIOSCIENCES INC · $8.28M
Fully Exited (vs previous quarter)
- EWTX EDGEWISE THERAPEUTICS INC · prev qtr: $48.15M
- INSP INSPIRE MED SYS INC COM · prev qtr: $5.14M
- PEN PENUMBRA INC · prev qtr: $4.03M
- RNA ATRIUM THERAPEUTICS INC · prev qtr: $3.52M
- MASI MASIMO CORP · prev qtr: $1.56M
- EQNR EQUINOR ASA · prev qtr: $741.58K
- XOM EXXONMOBIL HLDGS CORP · prev qtr: $741.41K
- BP BP P L C FSPONSORED ADR 1 ADR REPS 6 ORD SHS · prev qtr: $735.27K
Insider Transactions (Form 4)
Latest Bellevue Group AG buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Bellevue Group AG files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 148 positions worth $4.75B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 148 positions · $4.75B reported value (Q2 2026)
- Top 10 holdings = 42.9% of reported value
- Largest position: AMGN (AMGEN INC) at 6.5%
- Average position size: $32.11M
Sector Tilt
- Health Care 92.6%
- Industrials 1.7%
- Information Technology 0.4%
- (classified holdings cover 95% of value)
Quarterly Activity
- Q2 2026: 17 new, 39 added, 64 reduced, 24 exited
- 28 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
851.55K | $308.36M | 6.49% | Add | |
| 2 |
|
578.63K | $287.42M | 6.05% | Reduce | |
| 3 |
|
301.00K | $279.26M | 5.88% | Reduce | |
| 4 |
|
2.16M | $272.74M | 5.74% | Add | |
| 5 |
|
1.05M | $196.27M | 4.13% | Reduce | |
| 6 |
|
1.66M | $157.71M | 3.32% | Add | |
| 7 |
|
1.39M | $148.57M | 3.13% | Add | |
| 8 |
|
2.45M | $134.73M | 2.83% | Reduce | |
| 9 |
|
1.05M | $130.08M | 2.74% | Hold | |
| 10 |
|
6.73M | $123.67M | 2.60% | Hold | |
| 11 |
|
6.19M | $115.74M | 2.44% | Reduce | |
| 12 |
|
1.97M | $114.63M | 2.41% | Add | |
| 13 |
|
188.51K | $102.14M | 2.15% | Add | |
| 14 |
|
254.81K | $101.33M | 2.13% | Reduce | |
| 15 |
|
157.29K | $98.08M | 2.06% | Reduce | |
| 16 |
|
2.62M | $98.04M | 2.06% | Reduce | |
| 17 |
|
1.19M | $88.59M | 1.86% | Add | |
| 18 |
|
2.79M | $88.53M | 1.86% | Hold | |
| 19 |
|
947.12K | $85.94M | 1.81% | Reduce | |
| 20 |
|
268.46K | $84.52M | 1.78% | Add | |
| 21 |
|
994.23K | $77.78M | 1.64% | Add | |
| 22 |
|
972.26K | $77.09M | 1.62% | Reduce | |
| 23 |
|
1.49M | $75.62M | 1.59% | Reduce | |
| 24 |
|
1.71M | $73.41M | 1.54% | Hold | |
| 25 |
|
3.06M | $67.95M | 1.43% | Reduce | |
| 26 |
|
739.23K | $66.87M | 1.41% | Reduce | |
| 27 |
|
1.98M | $66.20M | 1.39% | Reduce | |
| 28 |
|
149.13K | $61.98M | 1.30% | Add | |
| 29 |
|
822.49K | $55.39M | 1.17% | Add | |
| 30 |
|
1.20M | $44.65M | 0.94% | Hold | |
| 31 |
|
1.35M | $44.44M | 0.94% | New | |
| 32 |
|
1.62M | $42.11M | 0.89% | Reduce | |
| 33 |
|
560.00K | $40.96M | 0.86% | Add | |
| 34 |
|
79.82K | $40.02M | 0.84% | Add | |
| 35 |
|
887.65K | $37.88M | 0.80% | Reduce | |
| 36 |
|
29.88K | $35.84M | 0.75% | Reduce | |
| 37 |
|
493.60K | $35.07M | 0.74% | New | |
| 38 |
|
61.78K | $32.52M | 0.68% | Reduce | |
| 39 |
|
148.19K | $28.88M | 0.61% | Reduce | |
| 40 |
|
77.53K | $28.82M | 0.61% | Reduce | |
| 41 |
|
1.19M | $28.80M | 0.61% | Reduce | |
| 42 |
|
143.84K | $27.40M | 0.58% | Reduce | |
| 43 |
|
103.28K | $26.23M | 0.55% | Reduce | |
| 44 |
|
1.10M | $23.89M | 0.50% | New | |
| 45 |
|
155.00K | $23.69M | 0.50% | New | |
| 46 |
|
139.68K | $23.56M | 0.50% | Hold | |
| 47 |
|
4.10M | $23.41M | 0.49% | Reduce | |
| 48 |
|
58.40K | $23.20M | 0.49% | Reduce | |
| 49 |
|
56.45K | $21.83M | 0.46% | Add | |
| 50 |
|
694.18K | $21.70M | 0.46% | Reduce | |
FAQ
What did Bellevue Group AG buy in 2026-Q2?
In its 2026-Q2 13F filing, Bellevue Group AG reported 148 equity positions worth $4.75B in aggregate; its largest disclosed positions were AMGN ($308.36M), VRTX ($287.42M), ARGX ($279.26M).
How large is Bellevue Group AG's portfolio?
Bellevue Group AG reported $4.75B of long equity holdings across 148 positions as of 2026-Q2. Top-10 holdings account for 42.9% of reported value.
What is Bellevue Group AG's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.